



CLAIMS

1. Use of a compound of Structure I, a tautomer of the compound, a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable salt of the tautomer, or a mixture thereof, in the preparation of a medicament for treating a metastasized cancer in a subject, wherein the metastasized cancer is renal cancer, bladder cancer, gastric cancer, endometrial cancer, salivary gland cancer, adrenal cancer, pancreatic cancer, ovarian cancer, peritoneal cancer, head and neck cancer, colorectal cancer, or glioblastoma, and wherein the compound of Structure I is:



wherein,

A is a group having the following Structure:




wherein,

R¹ is selected from straight or branched chain alkyl groups having from 1 to 6 carbon atoms, and

further wherein, the growth of the metastasized tumor in the subject is inhibited after administration of the compound of Structure I, the tautomer of the compound, the

pharmaceutically acceptable salt of the compound, the pharmaceutically acceptable salt of the tautomer, or the mixture thereof to the subject.

2. The use of claim 1, wherein R^1 is a methyl group, and the compound of Structure I has the Structure IA



IA

3. The use of claim 1, wherein the lactate salt of the compound of Structure I or the tautomer thereof is used to prepare the medicament.

4. The use of claim 1, wherein the medicament further comprises a second agent.

5. The use of claim 4, wherein the second agent is for the treatment of osteoporosis.

6. The use of claim 5, wherein the second agent is a bisphosphonate.


7. The use of claim 4, wherein the second agent is an anticancer agent.

8. The use of any one of claims 1-7, wherein the metastasized cancer is renal cancer or bladder cancer.

9. The use of any one of claims 1-7, wherein the cancer has metastasized to a bone in the subject.

Claims

1. A compound of Structure I, a tautomer of the compound, a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable salt of the tautomer, or a mixture thereof,



I

wherein,


A is a group of the following Structure:



wherein, R¹ is selected from straight or branched chain alkyl groups having from 1 to 6 carbon atoms, for use in a method of treating a metastasized cancer in a subject, wherein said subject is suffering from prostate cancer, and

wherein the growth of the tumor in the subject is inhibited after administration of the compound of Structure I, the tautomer of the compound, the pharmaceutically acceptable salt of the compound, the pharmaceutically acceptable salt of the tautomer, or the mixture thereof to the subject.

2. The compound for use according to claim 1, wherein R¹ is a methyl group, and the compound of Structure I has the Structure IA



IA

3. The compound for use according to claim 1 wherein said treatment comprises administering a second agent to the subject.
4. The compound for use according to claim 1, wherein the lactate salt of the compound of Structure I or the tautomer thereof is administered to the subject.
5. The compound for use according to any one of claims 1-4, wherein the cancer is a solid tumor.
6. The compound for use according to claim 1, wherein the cancer has metastasized to a bone in the subject.
7. The compound for use according to any one of claims 1-4, wherein the subject is a prostate cancer patient, and the patient is a human.
8. The compound for use according to claim 3, wherein the second agent is for the treatment of osteoporosis.
9. The compound for use according to claim 8 wherein the second agent is a bisphosphonate.
10. The compound for use according to claim 3 wherein the second agent is an anticancer agent.